oxycodone trials, page-2

and more on the very attractive deal on animal health. As Esra says it goes across the full spectrum of animal drugs. because it is hard for owner to give needles or pills to their animals. This might be a lot bigger and more lucrative than we POHsters have realised.

"DESLEY BLANCH : Well, the versatility of the TPM technology is that it can be formulated as you say as a liquid, a patch, a spray or gel and will deliver these large molecules, such as insulin through the skin and into the blood stream. Now you've entered the veterinary market for the treatment of diabetes in companion animals. So what's the deal that you have struck?

DR ESRA OGRU : When you look at the veterinarian application of drugs, they are very similar to humans, so if a drug is being used in oncology it is most likely it's going to be used in the veterinary market as well. But the problem with the vet market is obviously it is much, much smaller.

So because of the commercialisation strategy we have taken on board, we want to be able to maximise and leverage on TPM. So we have struck a very attractive deal with Novartis Animal Health. They are a global player in the field. To be able to avoid injections which is costly and you don't want to say bye to your pets, so you want to be able to assist and treat your pet, so moving away from injections and oral therapies, a patch is perfect for a veterinary application.

DESLEY BLANCH : And trying to put a needle into a dog isn't that easy.

DR ESRA OGRU : It's not, or a cat, so it's very difficult. So this is a very unique way of treating the disease."